Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:

Inclusion Criteria:

- Patients much have histologically confirmed adenocarcinoma of the colon or rectum.

- Patients must have measurable recurrence or metastases in the liver and/or lungs.

- Patients must have prior chemotherapy for advanced colorectal cancer and have
previously received both an oxaliplatin and an irinotecan based regimen.

- Age > 18 years.

- Life expectancy greater than 4 weeks.

- ECOG performance status <3.

- Patients must have normal organ and marrow function.

- Patients must be able to swallow capsules.

- Patients must be able to understand and willing to sign a written informed consent
document.

- Patients are included regardless of KRAS/BRAF status.

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier.

- Patients may not be receiving any other investigational agent.

- Patients with know brain metastases should be excluded from this clinical trial
because they often develop progressive neurological dysfunction that would confound
the evaluation of neurologic and other adverse events.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to quinacrine, capecitabine or fluorouracil.

- The concomitant use of quinacrine and primaquine is contraindicated.

- Uncontrolled intercurrent illness including but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study.

- Patients with a baseline creatinine clearance of < 50 mL/min.

- Patients must be currently not treated with quinacrine or drugs related to
quinacrine.

- Patients who require anti-arrhythmic treatment with amiodarone or any drug with a
quinidine-like effect on the heart or who have history of a malignant ventricular
arrhythmia unless they have a functioning automatic implantable cardio defibrillator
implanted.

- Patients who have a history of noninfectious hepatitis or alcoholism.

- Patients with a lifetime history of porphyria or psoriasis because it can exacerbate
these conditions.

- Patients with documented glucose-6-phosphate dehydrogenase deficiency.

- Patients with a lifetime history of seizure disorder.

- Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any
medication.

- Patients with know dihydropyrimidine dehydrogenase deficiency.